Table 1 Baseline characteristics of the LISA study population—patients, tumor and treatment related characteristics in subjects in the lifestyle intervention arm and education only arm.

From: The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer

  Education only arm Lifestyle intervention arm characteristic
Randomized, N 167 171
Stratum
BMI (kg/m2)
 24–30, N (%) 76 (45.5) 73 (42.7)
 >30, N (%) 91 (54.5) 98 (57.3)
Prior adjuvant chemotherapy
 Yes, N (%) 96 (57.5) 96 (56.1)
 No, N (%) 71 (42.5) 75 (43.9)
Intervention language
 English, N (%) 147 (88.0) 151 (88.3)
 French, N (%) 20 (12.0) 20 (11.7)
Demographics
Age
 Mean (SD) 60.4 (7.8) 61.6 (6.7)
Race
 White, N (%) 162 (97.0) 161 (94.2)
 Asian, N (%) 3 (1.8) 3 (1.8)
 Black, N (%) 0 (0.0) 4 (2.3)
 Native, N (%) 0 (0.0) 1 (0.6)
 Other, N (%) 2 (1.2) 2 (1.2)
Height (cm)
 Mean (SD) 161.6 (6.2) 162.0 (6.4)
Weight (kg)
 Mean (SD) 81.0 (14.4) 82.7 (15.3)
Body mass index
 Mean (SD) 31.1 (5.3) 31.4 (5.0)
 Median (range) 30.4 (24.0–55.2) 30.7 (24.0–60.7)
Smoking history
 Currently, N (%) 15 (9.0) 9 (5.3)
 Previous (<6 months), N (%) 9 (5.4) 8 (4.7)
 Previous (>6 months), N (%) 60 (35.9) 72 (42.1)
 Never, N (%) 83 (49.7) 82 (48.0)
Marital status
 Currently married, N (%) 119 (71.3) 123 (71.9)
 Single, N (%) 12 (7.2) 18 (10.5)
 Widowed, N (%) 12 (7.2) 12 (7.0)
 Divorced/separated, N (%) 22 (13.2) 18 (10.5)
 Not given, N (%) 2 (1.2) 0 (0.0)
Living situation
 Spouse/partner and children, N (%) 24 (14.4) 27 (15.8)
 Spouse/partner only, N (%) 91 (54.5) 91 (53.2)
 Children only, N (%) 8 (4.8) 7 (4.1)
 Other relatives, N (%) 5 (3.0) 7 (4.1)
Other non-relatives, N (%) 1 (0.6) 2 (1.2)
 Alone, N (%) 35 (21.0) 32 (18.7)
 Other, N (%) 3 (1.8) 5 (2.9)
Tumour characteristics
T status
 1, N 9%) 103 (61.7) 114 (66.7)
 2, N (%) 56 (33.5) 47 (27.5)
 3, N (%) 6 (3.6) 10 (5.9)
 Missing/NA 1 (0.6) 0 (0.0)
N status
 0, N (%) 106 (63.5) 107 (62.6)
 1, N (%) 54 (32.3) 49 (28.7)
 2, N (%) 6 (3.6) 14 (8.2)
 3a, N(%) 1 (0.6) 1 (0.6)
Overall grade
 I, N (%) 41 (24.6) 38 (22.2)
 II, N (%) 73 (43.7) 96 (56.1)
 III, N (%) 51 (30.5) 37 (21.6)
 Missing/NA, N (%) 2 (1.2) 0 (0.0)
ER status
 Positive, N (%) 166 (99.4) 167 (97.7)
 Negative, N (%) 1 (0.6) 4 (2.3)
PR status
 Positive, N (%) 145 (86.8) 144 (84.2)
 Negative, N (%) 21 (12.6) 27 (15.8)
 Missing/NA, N (%) 1 (0.6) 0 (0.0)
HER2 status
 Positive, N (%) 25 (15.0) 15 (8.8)
 Negative, N (%) 138 (82.6) 153 (89.5)
 Missing/NA, N (%) 4 (2.4) 3 (1.8)
Prior treatment
Irradiation therapy
 No, N (%) 42 (25.2) 33 (19.3)
 Yes, N (%) 125 (74.9) 138 (80.7)
Surgery type
 Mastectomy, N (%) 64 (38.3) 60 (35.1)
 Lumpectomy, N (%) 113 (67.7) 120 (70.2)
 Axillary node dissection, N (%) 94 (56.3) 96 (56.1)
 Sentinel node biopsy, N (%) 113 (67.7) 108 (63.2)
Systemic chemotherapy
 No, N (%) 69 (41.3) 75 (43.9)
 Yes, N (%) 98 (58.7) 96 (56.1)
Chemo- and endocrine therapy type
 AC, N (%) 17 (10.2) 13 (7.6)
 AC Taxol, N (%) 29 (17.4) 21 (12.3)
 FEC 100, N (%) 5 (3.0) 11 (6.4)
 FEC Taxotere, N (%) 24 (14.4) 28 (16.4)
 CEF, N (%) 2 (1.2) 0 (0.0)
 Tamoxifen, N (%) 14 (8.4) 11 (6.4)
 Anastrozole, N (%) 8 (4.8) 8 (4.7)
 Exemestane, N (%) 2 (1.2) 0 (0.0)
 Herceptin, N (%) 24 (14.4) 12 (7.0)
 Lapatinib, N (%) 0 0
Months from diagnosis
 median (range)
9.1 (2.0–37.0b) 9.4 (1.6–92.0b)
Months from definitive surgery
 median (range)
7.3 (1.0–34.9) 7.6 (0.2–91.6)
  1. BMI body mass index, SD standard deviation, NA not available, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, AC Adriamycin-cyclophosphamide, FEC fluouracil-epirubicin-cyclophosphamide, CEF cyclophosphamide-epirubicin-fluouracil.
  2. aN3 patients were included in initial protocol.
  3. bOne patient was diagnosed 7.7 (waiver) years prior to trial randomization. Two lifestyle intervention arm patients and two education only arm subjects were diagnosed between 36 to 39 months prior to randomization, however, surgery was <36 months prior to randomization. All other patients were diagnosed <36 months prior to randomization.